- ASLAN Pharmaceuticals (NASDAQ:ASLN) -34% despite 'positive' ASLAN004 data in atopic dermatitis.
- Sentage Holdings (NASDAQ:SNTG) -15%.
- ReWalk Robotics (NASDAQ:RWLK) -14% on $32.5M equity offering priced at premium to market.
- ZIVO Bioscience (NASDAQ:ZIVO) -10%.
- Unique Fabricating (NYSE:UFAB) -8%.
- Capricor Therapeutics (NASDAQ:CAPR) -8%.
- Ensysce Biosciences (NASDAQ:ENSC) -7% on $15M convertible note financing.
- Huaneng Power International (NYSE:HNP) -6%.
- Biohaven Pharmaceutical Holding (NYSE:BHVN) -6% after verdiperstat multiple system atrophy trial data.
- Elite Education Group International (NASDAQ:EEIQ) -6%.